Cargando…

Costs and renumeration of osteomyelitis treatment involving free flaps: implications of return to theatre

Aim: This study aimed to define the costs of surgical management of chronic osteomyelitis where free tissue transfer was required in addition to debridement of bone, particularly the increased costs incurred by a return to theatre. We hypothesised that there would be a significantly greater cost whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirley, Rebecca, Fazekas, Janka, McNally, Martin, Ramsden, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852843/
https://www.ncbi.nlm.nih.gov/pubmed/29545991
http://dx.doi.org/10.7150/jbji.22186
_version_ 1783306647830003712
author Shirley, Rebecca
Fazekas, Janka
McNally, Martin
Ramsden, Alex
author_facet Shirley, Rebecca
Fazekas, Janka
McNally, Martin
Ramsden, Alex
author_sort Shirley, Rebecca
collection PubMed
description Aim: This study aimed to define the costs of surgical management of chronic osteomyelitis where free tissue transfer was required in addition to debridement of bone, particularly the increased costs incurred by a return to theatre. We hypothesised that there would be a significantly greater cost when patients required re-exploration for vascular compromise. Method: We retrospectively analysed the costs of a consecutive series of sixty patient episodes treated at the Bone Infection Unit in Oxford from 2012 to 2015. Treatment involved excision of osteomyelitis with free tissue transfer for immediate soft tissue cover. We compared the costs of uncomplicated cases with those who returned to theatre and determined the profit / loss for the hospital from renumeration through the UK National Health Service Tariff Structure. Results: Hospital income according to UK HRG tariff was compared to the actual cost of treatment and these 60 cases were significantly underfunded overall (P < 0.005). In just 1 case, the cost to the hospital was completely covered by tariff. Six patients (10%) returned to theatre for urgent flap re-exploration with five flaps salvaged and one failed, requiring another free flap reconstruction (1.7%). These six patient episodes had a significantly higher mean cost compared to the uncomplicated cases. The average financial loss to the hospital for patients who did return to theatre was £19401 (range £8103 to £48380) and in those who did not was £9600 (range - £600 to £23717). The case requiring further free tissue transfer cost a total of £74158, £48380 more than the hospital was paid: the most extreme discrepancy. The overall loss for this group of 60 patients was £610 090. Conclusions: Surgery for chronic osteomyelitis is multidisciplinary, complex and therefore expensive with a significant risk of complications. However, this study demonstrates that the hospital currently makes a financial loss on almost all patients but especially if flap complications occur. This study has implications for the long term viability of specialist units treating this important disease.
format Online
Article
Text
id pubmed-5852843
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-58528432018-03-15 Costs and renumeration of osteomyelitis treatment involving free flaps: implications of return to theatre Shirley, Rebecca Fazekas, Janka McNally, Martin Ramsden, Alex J Bone Jt Infect Research Paper Aim: This study aimed to define the costs of surgical management of chronic osteomyelitis where free tissue transfer was required in addition to debridement of bone, particularly the increased costs incurred by a return to theatre. We hypothesised that there would be a significantly greater cost when patients required re-exploration for vascular compromise. Method: We retrospectively analysed the costs of a consecutive series of sixty patient episodes treated at the Bone Infection Unit in Oxford from 2012 to 2015. Treatment involved excision of osteomyelitis with free tissue transfer for immediate soft tissue cover. We compared the costs of uncomplicated cases with those who returned to theatre and determined the profit / loss for the hospital from renumeration through the UK National Health Service Tariff Structure. Results: Hospital income according to UK HRG tariff was compared to the actual cost of treatment and these 60 cases were significantly underfunded overall (P < 0.005). In just 1 case, the cost to the hospital was completely covered by tariff. Six patients (10%) returned to theatre for urgent flap re-exploration with five flaps salvaged and one failed, requiring another free flap reconstruction (1.7%). These six patient episodes had a significantly higher mean cost compared to the uncomplicated cases. The average financial loss to the hospital for patients who did return to theatre was £19401 (range £8103 to £48380) and in those who did not was £9600 (range - £600 to £23717). The case requiring further free tissue transfer cost a total of £74158, £48380 more than the hospital was paid: the most extreme discrepancy. The overall loss for this group of 60 patients was £610 090. Conclusions: Surgery for chronic osteomyelitis is multidisciplinary, complex and therefore expensive with a significant risk of complications. However, this study demonstrates that the hospital currently makes a financial loss on almost all patients but especially if flap complications occur. This study has implications for the long term viability of specialist units treating this important disease. Ivyspring International Publisher 2018-02-05 /pmc/articles/PMC5852843/ /pubmed/29545991 http://dx.doi.org/10.7150/jbji.22186 Text en © The authors This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Shirley, Rebecca
Fazekas, Janka
McNally, Martin
Ramsden, Alex
Costs and renumeration of osteomyelitis treatment involving free flaps: implications of return to theatre
title Costs and renumeration of osteomyelitis treatment involving free flaps: implications of return to theatre
title_full Costs and renumeration of osteomyelitis treatment involving free flaps: implications of return to theatre
title_fullStr Costs and renumeration of osteomyelitis treatment involving free flaps: implications of return to theatre
title_full_unstemmed Costs and renumeration of osteomyelitis treatment involving free flaps: implications of return to theatre
title_short Costs and renumeration of osteomyelitis treatment involving free flaps: implications of return to theatre
title_sort costs and renumeration of osteomyelitis treatment involving free flaps: implications of return to theatre
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852843/
https://www.ncbi.nlm.nih.gov/pubmed/29545991
http://dx.doi.org/10.7150/jbji.22186
work_keys_str_mv AT shirleyrebecca costsandrenumerationofosteomyelitistreatmentinvolvingfreeflapsimplicationsofreturntotheatre
AT fazekasjanka costsandrenumerationofosteomyelitistreatmentinvolvingfreeflapsimplicationsofreturntotheatre
AT mcnallymartin costsandrenumerationofosteomyelitistreatmentinvolvingfreeflapsimplicationsofreturntotheatre
AT ramsdenalex costsandrenumerationofosteomyelitistreatmentinvolvingfreeflapsimplicationsofreturntotheatre